NCT01945788Unknown4 期
Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo
Bio Sidus SA1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Change from baseline in Bone mineral Density at 6 months.
研究概览
简要总结
The primary objective of this study is to compare efficacy and safety of two formulations of teriparatide 20 mcg/day plus calcium and vitamin D in postmenopausal women with osteoporosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 81 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •II. Age greater than or equal to 50 and less than 81 years.
- •III. Last menstrual period at least one year prior to signing the informed consent.
- •IV. Osteoporosis. Defined by the presence of:
- •BMD by DEXA with a T-score of -2.5 or lower on lumbar spine or T-score at the lumbar spine, femoral neck or total hip -2.0 or below, together with one or more vertebral fractures documented by lateral spine radiographs.
- •V. Have signed the informed consent
排除标准
- •I Bone alkaline phosphatase in the blood above the normal limit without any explanation.
- •II. Liver disease (AST or ALT> 2 x ULN). III. Renal disease (serum creatinine> 2.0 mg / dl) and / or creatinine clearance <30 ml / min IV. Hypercalcemia ([Ca]> 10.5 mg / dL). Patients with elevated PTH in the presence of albumin-corrected calcium within normal values can be re-evaluated.
- •V. Elevated blood PTH ([PTH]> 65 pg / ml) Patients with elevated PTH in the presence of albumin-corrected calcium within normal values can be re-evaluated.
- •VI. • Deficiency of vitamin D (25-OH vitamin D <16 ng / ml) or excess vitamin D (above 80 ng / ml blood). Patients who did not meet the inclusion criteria for vitamin D may receive a supplement (vitamin D) and be re-evaluated.
- •VII. • Anemia (hematocrit <32%).
- •VIII. • History of cancer (except basal cell carcinoma) or radiotherapy.
- •IX. Severe cardiopulmonary disease, including coronary heart disease: unstable angina, heart failure class III or IV or any other condition that the investigator believes may prevent participation safely and complete the protocol procedures.
- •X. Major psychiatric disease that in the opinion of the investigator, would prevent to give properinformed consent or complete the study procedures.
- •XI. Excessive alcohol or substance abuse that in the opinion of the investigator prevents giving informed consent or complete proper protocol procedures.
- •XII. Congenital or acquired bone disease, other than osteoporosis (including osteomalacia, hyperparathyroidism or Paget's disease)
- •XIII. Regarding the history of ingestion of oral bisphosphonates: After assessment of adequate adherence (compliance greater than 75%), if the patient received six months of treatment, she should have a bisphosphonate-free period of six months. If she took more than six months, the bisphosphonate-free period must be 12 months.
- •XIV. Current or within the last 3 months before study entry estrogen use, selective estrogen receptor modulators use or calcitonin use in therapeutic doses.
- •XV. Current use of systemic corticosteroids (oral or parenteral) for more than 14 days in the last 6 months. Vaginal estrogen and isoflavones are permitted .
- •XVI.Current or previous use of teriparatide, other PTH analogues as patches or injectables, strontium, fluorine or any intravenous bisphosphonate therapeutic dose, XVII. Known hypersensitivity to pharmaceuticals derived from bacterial cells. XVIII. Hypersensitivity to teriparatide or to any of its excipients. XIX.Nephrolithiasis or urolithiasis in activity, according to the investigator opinion in the 5 years prior to randomization.
- •XX.Inflammatory bowel disease, malabsorption syndrome or any sign of intestinal calcium malabsorption
- •XXI. Treatment with androgens or anabolic steroids in the 6 months prior to randomization.
- •XXII. Any medical condition that in the investigator opinion would contraindicate treatment with an investigational drug.
- •XXIII. Treatment with coumarin and indandione derivatives in the 3 months prior to randomization or treatment with heparins (at doses> 10,000 U / day) for more than 30 days in the 6 months prior to randomization.
- •XXIV.Treatment with any other drug known to affect bone metabolism, in therapeutic doses,in the 6 months prior to randomization.
- •XXV.Treatment with an investigational drug during the month prior to randomization. -
研究组 & 干预措施
Teriparatide Forteo
Active Comparator
20 micrograms/day plus calcium and vitamin D
干预措施: Teriparatide (rDNA origin) (Drug)
Teriparatide Osteofortil
Experimental
20 micrograms/day plus calcium and vitamin D
干预措施: Teriparatide (rDNA origin) (Drug)
结局指标
主要结局
Change from baseline in Bone mineral Density at 6 months.
时间窗: Basal, Six months and One Year
次要结局
- Change from baseline in P1NP, Osteocalcin, C-terminal cross-linked telopeptide of type I collagen levels at 3 and 6 months(Basal, 3, 6 and 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.Essential TremorNCT00236496Johnson & Johnson Pharmaceutical Research & Development, L.L.C.223
已完成
3 期
A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine HeadachesMigraineNCT00210912Johnson & Johnson Pharmaceutical Research & Development, L.L.C.328
已完成
1 期
A Comparison Study of PF708 and Forteo in Healthy SubjectsOsteoporosisNCT02656810Pfenex, Inc70
已完成
1 期
The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.LUTS(Lower Urinary Tract Symptoms)Benign Prostatic HyperplasiaOveractive BladderNCT02494349Jeil Pharmaceutical Co., Ltd.54
已完成
2 期
Comparative study of the safety and therapeutic efficacy of oral steroids (betamethasone) in pulse dose and oral cyclosporine in the treatment of alopecia areata (patchy hair loss).CTRI/2019/01/017202Shibashis Chatterjee60